摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-羟基雌马酚 | 116719-38-1

中文名称
8-羟基雌马酚
中文别名
——
英文名称
8-Hydroxy-Equol
英文别名
4',7,8-trihydroxyisoflavane;HIR-301;3,4-Dihydro-7,8-dihydroxy-3-(4-hydroxyphenyl)-2H-1-benzopyran;3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromene-7,8-diol
8-羟基雌马酚化学式
CAS
116719-38-1
化学式
C15H14O4
mdl
——
分子量
258.274
InChiKey
JYTKPSXFNOBXQJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    476.9±45.0 °C(Predicted)
  • 密度:
    1.382±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    69.9
  • 氢给体数:
    3
  • 氢受体数:
    4

SDS

SDS:bd864bda0950f72e5ad501a83082a3d9
查看

反应信息

  • 作为产物:
    描述:
    对羟基苯乙腈盐酸硫酸 、 palladium 10% on activated carbon 、 三氟化硼乙醚甲基磺酰氯 、 zinc(II) chloride 作用下, 以 乙醚溶剂黄146 为溶剂, 反应 2.0h, 生成 8-羟基雌马酚
    参考文献:
    名称:
    Enzymatic Studies of Isoflavonoids as Selective and Potent Inhibitors of Human Leukocyte 5-Lipo-Oxygenase
    摘要:
    Continuing our search to find more potent and selective 5‐LOX inhibitors, we present now the enzymatic evaluation of seventeen isoflavones (IR) and nine isoflavans (HIR), and their in vitro and in cellulo potency against human leukocyte 5‐LOX. Of the 26 compounds tested, 10 isoflavones and 9 isoflavans possessed micromolar potency, but only three were selective against 5‐LOX (IR‐2, HIR‐303, and HIR‐309), with IC50 values at least 10 times lower than those of 12‐LOX, 15‐LOX‐1, and 15‐LOX‐2. Of these three, IR‐2 (6,7‐dihydroxy‐4‐methoxy‐isoflavone, known as texasin) was the most selective 5‐LOX inhibitor, with over 80‐fold potency difference compared with other isozymes; Steered Molecular Dynamics (SMD) studies supported these findings. The presence of the catechol group on ring A (6,7‐dihydroxy versus 7,8‐dihydroxy) correlated with their biological activity, but the reduction of ring C, converting the isoflavones to isoflavans, and the substituent positions on ring B did not affect their potency against 5‐LOX. Two of the most potent/selective inhibitors (HIR‐303 and HIR‐309) were reductive inhibitors and were potent against 5‐LOX in human whole blood, indicating that isoflavans can be potent and selective inhibitors against human leukocyte 5‐LOX in vitro and in cellulo.
    DOI:
    10.1111/cbdd.12469
点击查看最新优质反应信息

文献信息

  • Synthesis of Various Kinds of Isoflavones, Isoflavanes, and Biphenyl-Ketones and Their 1,1-Diphenyl-2-picrylhydrazyl Radical-Scavenging Activities
    作者:Hideyuki Goto、Yoshiyasu Terao、Shuji Akai
    DOI:10.1248/cpb.57.346
    日期:——
    Forty-eight kinds of isoflavones (8), thirty-one isoflavanes (9), and forty-seven biphenyl-ketones (10, 10′) were synthesized from eleven kinds of substituted phenols (11) and six phenylacetic acids (12). Among them, seventy-five compounds are new. The radical scavenging activities of these compounds were evaluated using 1,1-diphenyl-2-picrylhydrazyl (DPPH) at pH 6.0. We found that thirty-nine out of forty-three compounds having a catechol moiety on either the A- or the B-ring exhibited a high activity (ED50=12—54 μM) similar to that of catechin. In these cases, the remaining part of their structure seemed to have little effect on their activity. Many 6- or 8-hydroxyisoflavanes (9E—I) and their biphenyl-ketone derivatives (10E—H) also showed a high activity (ED50=<50 μM), while all of their corresponding isoflavones (8E—I) were not active at all. The 7-hydroxyisoflavanes having either an additional hydroxyl group at the C5-position (9D) or a methoxy group at the C6-position (9J) presented a high activity (ED50=26—32 μM). This study suggests that natural isoflavones have the possibilities of exhibiting antioxidant activities through the hydroxylation at the C6-, C8-, or C3′-position or the formation of the isoflavanes (9) and/or the biphenyl-ketone derivatives (10′) by metabolism or biotransformation.
    合成了四十八种异黄酮(8)、三十一种异黄烷(9)以及四十七种联苯酮(10, 10′),这些化合物是由十一种取代酚(11)和六种苯乙酸(12)合成的。其中,有七十五种化合物是新发现的。这些化合物的自由基清除活性在pH 6.0下使用1,1-二苯基-2-吡唑啉酮(DPPH)进行了评估。我们发现,在四十三种含有儿茶酚基的化合物中,三十九种在A环或B环上表现出与儿茶素相似的高活性(ED50=12—54 μM)。在这些情况下,它们结构的其他部分似乎对活性影响不大。许多6-或8-羟基异黄烷(9E—I)及其联苯酮衍生物(10E—H)也显示出高活性(ED50=<50 μM),而它们对应的异黄酮(8E—I)则完全没有活性。具有在C5位增加羟基(9D)或在C6位增加甲氧基(9J)的7-羟基异黄烷则展现出高活性(ED50=26—32 μM)。本研究表明,天然异黄酮通过在C6、C8或C3′位置的羟基化,或通过代谢或生物转化形成异黄烷(9)和/或联苯酮衍生物(10′),具有表现抗氧化活性的可能性。
  • Benzopyrans and use thereof in treating vascular diseases
    申请人:Zyma SA
    公开号:US04814346A1
    公开(公告)日:1989-03-21
    Isoflavans of the formula I ##STR1## wherein the groups OR, R', R" and ring B are as defined in the specification, exhibit valuable pharmacological properties, especially for the treatment of vascular diseases. They are prepared by methods known per se.
    公式为I ##STR1## 中的异黄酮,其中基团OR、R'、R"和环B的定义如规范中所述,具有有价值的药理特性,特别适用于治疗血管疾病。它们可通过已知的方法制备。
  • Bicyclic compounds
    申请人:Zyma SA
    公开号:EP0267155A2
    公开(公告)日:1988-05-11
    Isoflavans of the formula I wherein the groups OR, R', R" and ring B are as defined in the specification, exhibit valueable pharmacological properties, especially for the treatment of vascular diseases. They are prepared by methods known per se.
    式 I 的异黄酮(其中基团 OR、R'、R "和环 B 如说明书中所定义)具有宝贵的药理特性,特别是在治疗血管疾病方面。 它们是通过本身已知的方法制备的。
  • Anti-inflammatory Modalities
    申请人:Marshall Edwards, Inc.
    公开号:EP2526941A1
    公开(公告)日:2012-11-28
    Anti-inflammatory modalities are described with reference to select isoflavonoid compounds, compositions containing same and the use of said compounds and/or compositions in treatment, particularly for the treatment of inflammatory diseases and related conditions.
    抗炎模式的描述涉及精选的异黄酮化合物、含有异黄酮化合物的组合物以及所述化合物和/或组合物在治疗中的用途,特别是用于治疗炎症性疾病和相关病症。
  • US4814346A
    申请人:——
    公开号:US4814346A
    公开(公告)日:1989-03-21
查看更多